written by reader De-Teasing Mark Skousen’s “Swiss Army Bio-Knife”

By thesinns, February 24, 2020

Dr. Mark Skousen believes that a small Swiss research firm has discovered a cure for Rheumatoid Arthritis. He claims ”…This company is capable of making you rich no matter which direction the economy or investment markets are headed.” He doesn’t want you to buy the stock of the Swiss firm that discovered this biologic treatment for RA but rather the American Company that has partnered with the small Swiss outfit to produce and market this remarkable ”biologic” which is apparently doing well in phase two studies. A ”biologic” is a medication chemically built to include proteins or other molecules obtained from human cells. The Current RA market is served by sales of Tumor Necrosis Factor Blockers made by AbbVie (Humira), Amgen (Enbrel) and J&J (Remicade). Total annual sales of these TNF blockers are $46 B. But TNF Blockers have nasty side effects that will not happen with this new biologic.
I’m pretty sure this new biologic was designed by Philochem the research arm of Philogen which is privately held. So you can’t own the Swiss discoverer of the ”Swiss Army Bio-Knife”.
Dr. Skousen, who has a pretty good track record, claims that the American partner on this project (American X) ( an American ”Behemoth”) has total rights to produce and market this biologic and already has 2020 sales of $52 B which may well double with this new product. American X he claims already pays a 4% dividend and it’s not any of the above mentioned TNF Blocker manufacturers. Smells like Pfizer to me. For $49 Dr. Skousen just might confirm my suspicions for you. Thesinns

This is a discussion topic or guest posting submitted by a Stock Gumshoe reader. The content has not been edited or reviewed by Stock Gumshoe, and any opinions expressed are those of the author alone.

guest

12345

This site uses Akismet to reduce spam. Learn how your comment data is processed.

0 Comments
Inline Feedbacks
View all comments

We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies.

More Info